Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
SandpiperA Phase 1/2, Multicenter, Open-Label Trial of MG1 Maraba Expressing MAGEA3 (MG1-MAGEA3), with Adenovirus Vaccine Expressing MAGE-A3 (Ad-MAGEA3), in Combination with Pembrolizumab in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC)Juergens, Dr RosalynOpenNCT02879760
BAY 15743 Phase II trial of anetumab ravtansine (BAY 94-9343) in patients with advanced or metastatic malignant pleural mesothelioma (MPM) overexpressing mesothelin after first line treatment with platinum in combination with pemetrexedEllis, Dr PeterOpenNCT02610140
BR.31A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer.Juergens, Dr RosalynOpenNCT02273375
BR.34A Randomized Trial of Durvalumab (MEDI4736) and Tremelimumab +/- Platinum Based Chemotherapy in Patients with Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Juergens, Dr RosalynOpenNCT03057106
CA001030A Phase 1/2 Multicenter Study of BMS-986012 in Subjects with Relapsed/Refractory Small Cell Lung CancerJuergens, Dr RosalynOpenNCT02247349
FRACTION-LungA Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in
Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)
Juergens, Dr RosalynOpenNCT02750514
CLDK378A2112A multi-center, randomized open label study to assess the systemic exposure, efficacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)Juergens, Dr RosalynOpenNCT02299505
IND.227A Phase II Randomized Study of Pembrolizumab in Patients with Advanced Malignant Pleural MesotheliomaGoffin, Dr JohnOpenNCT02784171
LINNEARRE IPhase I study of neo-adjuvant stereotactic body radiotherapy (SBRT) in operable patients with borderline resectable locally advanced non-small cell lung cancer (NSCLC)Tsakiridis, Dr TheosOpenNCT02433574
M14-361A Phase 1 Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin Etoposide as a Therapy of Treatment Naïve Extensive Stage Disease Small Cell Lung CancerEllis, Dr PeterOpenNCT02289690
M16-289A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with
Topotecan for Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy
Ellis, Dr PeterOpenNCT03061812
OCOG-2013-LUSTREA Randomized Trial of Medically-Inoperable Stage I Non-Small Cell Lung Cancer Patients Comparing Stereotactic Body Radiotherapy Versus Conventional Radiotherapy (LUSTRE)Swaminath, Dr AnandOpenNCT01968941
OCOG-2014-ALMERAA Phase II Study to Investigate a Combination of Metformin with Chemo-Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer Advanced Lung Cancer Tsakiridis, Dr TheosOpenNCT02115464
ASTRISOpen Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation Positive Non Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy with an EGFR Tyrosine Kinase Inhibitor (EGFRTKI)The ASTRIS Study Juergens, Dr RosalynOpenNCT02474355
Download PDF